XERAVA is a new, fully synthetic, intravenous fluorocycline antibiotic recommended by a range of treatment guidelines in China and beyond. Credit: Kateryna Kon via shutterstock.com.
The collaboration will leverage SPH Kyuan’s drug import capabilities and distribution network, along with an improved logistics system.
SPH Kyuan’s capability will help to accelerate the commercialisation of XERAVA, and will offer benefits to patients and address vital unmet requirements across China.
XERAVA is a new, fully synthetic, intravenous fluorocycline antibiotic that has also been recommended by a range of treatment guidelines in China and beyond.
The antibiotic treats infections of susceptible gram-positive, gram-negative and anaerobic pathogens comprising multidrug-resistant (MDR) isolates.
Everest expects to introduce XERAVA commercially in mainland China in the third quarter of 2023.
Everest Medicines CEO Rogers Yongqing Luo stated: “We are very excited to reach a partnership with SPH Kyuan. SPH Kyuan’s rich experience in drug import and channel distribution will accelerate the delivery of XERAVA to hospitals and patients in need.
“This partnership marks another step towards the successful commercialisation of XERAVA, leading our pipeline with at least three more products expected to be approved in the next two years.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.